AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9098473 — intervention group
Group type: COMPARATOR
Intervention: Semen untreated (Control group)
Number of subjects: 0
Study 9098473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pellet-Swim-up (SU) treatment
Number of subjects: 0
Study 9098473 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation on Discontinuous Percoll Gradient (MP) treatment
Number of subjects: 0
Study 2694341 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone plus ORT
Number of subjects: 191
Study 2694341 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ORT
Number of subjects: 191
Study 2694341 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone plus ORT (in patients with fecal leukocytes)
Number of subjects: 191
Study 2694341 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ORT (in patients with fecal leukocytes)
Number of subjects: 191
Study 506799 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid administration for 24 hours during phenformin treatment
Number of subjects: 10
Study 506799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol administration to biguanide-treated diabetics
Number of subjects: 10
Study 506799 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin treatment
Number of subjects: 10
Study 506799 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 10
Study 31752000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate with high target bicarbonate level of 25 ± 1 mEq/L
Number of subjects: 42
Study 31752000 — intervention group
Group type: COMPARATOR
Intervention: Standard level of 22 ± 1 mEq/L (Control)
Number of subjects: 42
Study 31537089 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem-CR
Number of subjects: 103
Study 31537089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 27615436 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg per day
Number of subjects: 350
Study 27615436 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil 75 mg per day
Number of subjects: 350
Study 25345731 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion relieving pain
Number of subjects: 22
Study 25345731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain (mild and moderate intensities)
Number of subjects: 22
Study 25345731 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 22
Study 24085227 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 5963
Study 24085227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5963
Study 21895745 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine followed by two doses of pandemic H1N1 2009 vaccine (Group 1)
Number of subjects: 117
Study 21895745 — intervention group
Group type: COMPARATOR
Intervention: One dose of pandemic H1N1 2009 vaccine followed by simultaneous vaccination of seasonal trivalent vaccine and second dose of pandemic H1N1 2009 vaccine (Group 2)
Number of subjects: 117
Study 20050436 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based, multidisciplinary team-based education
Number of subjects: 0
Study 20050436 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education programs
Number of subjects: 0
Study 20050436 — intervention group
Group type: EXPERIMENTAL
Intervention: Education through dialysis centers
Number of subjects: 0
Study 16790484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tart cherry juice blend
Number of subjects: 14
Study 16790484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 14745745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic intervention (one‐to‐one support) with long‐term survivors (LTS) meeting 8 times in 8 weeks
Number of subjects: 30
Study 14745745 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 30
Study 11030199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal lactoferrin (Lf) test
Number of subjects: 351
Study 11030199 — intervention group
Group type: COMPARATOR
Intervention: Fecal occult blood (FOB) test
Number of subjects: 351
Study 9315575 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutamine
Number of subjects: 26
Study 9315575 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 26
Study 8397213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coating
Number of subjects: 27
Study 8397213 — intervention group
Group type: COMPARATOR
Intervention: Plasma-sprayed titanium alloy (Ti) coating
Number of subjects: 27
Study 3741249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% aqueous phenylephrine hydrochloride
Number of subjects: 30
Study 3741249 — intervention group
Group type: COMPARATOR
Intervention: 2.5% viscous phenylephrine hydrochloride
Number of subjects: 30
Study 28956169 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal mineral water treatment (n=26)
Number of subjects: 50
Study 28956169 — intervention group
Group type: COMPARATOR
Intervention: Tap water treatment (n=24)
Number of subjects: 50
Study 27636759 — intervention group
Group type: EXPERIMENTAL
Intervention: Apadent Total Care toothpaste with nanocalciumhydroxyapatite
Number of subjects: 30
Study 24793941 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars Toolkit and early vaccine supplies
Number of subjects: 20
Study 24793941 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 20
Study 23106928 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 39
Study 23106928 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 39
Study 20618338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 + Tanespimycin 50 mg/m2
Number of subjects: 0
Study 20618338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 + Tanespimycin 175 mg/m2
Number of subjects: 0
Study 20618338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 + Tanespimycin 340 mg/m2
Number of subjects: 0
Study 18312589 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg levodopa plus 25 mg carbidopa)
Number of subjects: 20
Study 18312589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16629292 — intervention group
Group type: EXPERIMENTAL
Intervention: Video glasses
Number of subjects: 24
Study 16629292 — intervention group
Group type: COMPARATOR
Intervention: Video projector
Number of subjects: 24
Study 16629292 — intervention group
Group type: EXPERIMENTAL
Intervention: Video glasses and video projector
Number of subjects: 24
Study 11916789 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium
Number of subjects: 0
Study 11916789 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium
Number of subjects: 0
Study 9459643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vena caval filter
Number of subjects: 400
Study 9459643 — intervention group
Group type: COMPARATOR
Intervention: No filter
Number of subjects: 400
Study 9459643 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 400
Study 9459643 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 400
Study 7624600 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine
Number of subjects: 127
Study 7624600 — intervention group
Group type: COMPARATOR
Intervention: 10% phenylephrine
Number of subjects: 127
Study 7624600 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine in both eyes
Number of subjects: 127
Study 7624600 — intervention group
Group type: COMPARATOR
Intervention: 10% phenylephrine in both eyes
Number of subjects: 127
Study 2096482 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus gland preparations (Thymu‐Skin)
Number of subjects: 0
Study 843177 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 0
Study 843177 — intervention group
Group type: EXPERIMENTAL
Intervention: Major role therapy (MRT)
Number of subjects: 0
Study 843177 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular medication adherence support (e.g., visiting nurse, long-acting medication)
Number of subjects: 0
Study 30409278 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with the SAPIEN XT valve
Number of subjects: 2032
Study 30409278 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 2032
Study 30409278 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2032
Study 27392024 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-piece IOL
Number of subjects: 65
Study 27392024 — intervention group
Group type: COMPARATOR
Intervention: Three-piece IOL
Number of subjects: 65
Study 24597619 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS paired with cyclic passive movement (400 pairs, 1 Hz)
Number of subjects: 7
Study 24597619 — intervention group
Group type: COMPARATOR
Intervention: TMS (120% of the resting motor threshold-RMT) with muscle at rest
Number of subjects: 7
Study 22696580 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs used in the MESS study
Number of subjects: 1334
Study 22696580 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG abnormality
Number of subjects: 1334
Study 22696580 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for partial seizures
Number of subjects: 1334
Study 21029175 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher benefit (up to $250 per month with a 20% copayment)
Number of subjects: 1605
Study 18842771 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg dairy calcium supplementation per day for 5 weeks
Number of subjects: 10
Study 18842771 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 10
Study 18842771 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release caffeine (SRC; 300 mg)
Number of subjects: 10
Study 18842771 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 10
Study 16102616 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 397
Study 16102616 — intervention group
Group type: COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 397
Study 11847518 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite instability assessment in leukemic DNA from bone marrow
Number of subjects: 43
Study 11847518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis
Number of subjects: 43
Study 10561643 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 10
Study 10561643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulipan‐Bruner trocar
Number of subjects: 10
Study 8908381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.7 g/day eicosapentaenoic plus docosahexaenoic acid for 2 months, then 1.7 g/day for 4 more months)
Number of subjects: 16
Study 8908381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8908381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 16
Study 1985383 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 77
Study 6613136 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen cryoprecipitate, thrombin solution, and factor XIII concentrate used for gluing in suprapubic transvesical prostatectomy
Number of subjects: 0
Study 31969184 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab
Number of subjects: 0
Study 31277659 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy
Number of subjects: 359
Study 31277659 — intervention group
Group type: COMPARATOR
Intervention: Transbronchial forceps biopsy
Number of subjects: 359
Study 27091470 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal fry in unstressed syllables
Number of subjects: 50
Study 27091470 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal fry occurrence
Number of subjects: 50
Study 27091470 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from stressed syllable
Number of subjects: 50
Study 27091470 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal fry use variability
Number of subjects: 50
Study 27091470 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-syllable nonwords
Number of subjects: 50
Study 27091470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical stress impact
Number of subjects: 50
Study 25958945 — intervention group
Group type: EXPERIMENTAL
Intervention: Overreaching-detraining (OR-DT)
Number of subjects: 24
Study 25958945 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study 24968985 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day of quetiapine
Number of subjects: 95
Study 24968985 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of quetiapine
Number of subjects: 95
Study 24968985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 22577652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone mineral (BBM) without collagen membrane
Number of subjects: 23
Study 22577652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone mineral (BBM) with collagen membrane
Number of subjects: 23
Study 22577652 — intervention group
Group type: COMPARATOR
Intervention: Comparison between BBM and BBM with collagen membrane
Number of subjects: 23
Study 19064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Reacted spermatozoa
Number of subjects: 71
Study 19064263 — intervention group
Group type: COMPARATOR
Intervention: Nonreacted spermatozoa
Number of subjects: 71
Study 19064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Both reacted and nonreacted spermatozoa
Number of subjects: 71
Study 17569063 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% phenylephrine
Number of subjects: 35
Study 17569063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 16236038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (four doses of 100 mg over 2 days)
Number of subjects: 7
Study 16236038 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (single 250 mg dose)
Number of subjects: 7
Study 16236038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (four doses of 100 mg over 2 days) + Caffeine (single 250 mg dose)
Number of subjects: 7
Study 11832877 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench/step exercise with extremity loading (WT)
Number of subjects: 44
Study 11832877 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench/step exercise without extremity loading (NWT)
Number of subjects: 44
Study 11832877 — intervention group
Group type: COMPARATOR
Intervention: Non-training controls (NTC)
Number of subjects: 44
Study 10431944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostility-reduction intervention (N = 10)
Number of subjects: 22
Study 10431944 — intervention group
Group type: COMPARATOR
Intervention: Information-control group (N = 12)
Number of subjects: 22
Study 7668949 — intervention group
Group type: EXPERIMENTAL
Intervention: Blank card, colorful photograph, no stimulus
Number of subjects: 6
Study 2152233 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 240 mg/day
Number of subjects: 12
Study 2152233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2152233 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60 to 240 mg/day)
Number of subjects: 12
Study 2152233 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 12
Study 6619296 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home training of parents and child
Number of subjects: 23
Study 6619296 — intervention group
Group type: EXPERIMENTAL
Intervention: Office based training of parents and child
Number of subjects: 23
Study 6619296 — intervention group
Group type: EXPERIMENTAL
Intervention: Office based training of parents only
Number of subjects: 23
Study 6619296 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 23
Study 31003148 — intervention group
Group type: EXPERIMENTAL
Intervention: Guluronic acid (G2013)
Number of subjects: 75
Study 31003148 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 75
Study 31003148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31003148 — intervention group
Group type: EXPERIMENTAL
Intervention: Guluronic acid and Naproxen
Number of subjects: 75
Study 31003148 — intervention group
Group type: EXPERIMENTAL
Intervention: Guluronic acid
Number of subjects: 75
Study 28976985 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent in company of friends
Number of subjects: 138
Study 28976985 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 138
Study 26245756 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 26245756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26245756 — intervention group
Group type: EXPERIMENTAL
Intervention: PSpARC response criteria
Number of subjects: 0
Study 26245756 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR response criteria
Number of subjects: 0
Study 26245756 — intervention group
Group type: COMPARATOR
Intervention: ASDAS and BASDAI response criteria
Number of subjects: 0
Study 25032771 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable collagen barriers supported by an osteosynthesis plate
Number of subjects: 22
Study 25032771 — intervention group
Group type: COMPARATOR
Intervention: Nonresorbable titanium‐reinforced expanded polytetrafluoroethylene barriers (control)
Number of subjects: 22
Study 25032771 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 22
Study 18511533 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive pragmatic manual therapy programme including specific corticosteroid injections (n = 89)
Number of subjects: 160
Study 18511533 — intervention group
Group type: COMPARATOR
Intervention: Standardized optimized activating care (n = 71)
Number of subjects: 160
Study 15519086 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsuction ring (19.0 mm diameter)
Number of subjects: 33
Study 15519086 — intervention group
Group type: COMPARATOR
Intervention: Standard suction ring (20.3 mm diameter)
Number of subjects: 33
Study 10674267 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole/day for 8 weeks
Number of subjects: 295
Study 10674267 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 or 30 mg lansoprazole long-term treatment
Number of subjects: 295
Study 10674267 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole long-term treatment
Number of subjects: 295
Study 10674267 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up after 3 months
Number of subjects: 295
Study 9484683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate tissue glue
Number of subjects: 86
Study 9484683 — intervention group
Group type: COMPARATOR
Intervention: Suturing with interrupted 4/0 plain catgut
Number of subjects: 86
Study 8318561 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-identical platelets
Number of subjects: 0
Study 8318561 — intervention group
Group type: COMPARATOR
Intervention: ABO-unmatched platelets
Number of subjects: 0
Study 8318561 — intervention group
Group type: COMPARATOR
Intervention: ABO-incompatible plasma transfusions
Number of subjects: 0
Study 8318561 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-identical transfusions
Number of subjects: 0
Study 3525694 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'-Fluoro-5-iodoarabinosylcytosine (FIAC)
Number of subjects: 34
Study 3525694 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside (ara-A)
Number of subjects: 34
Study 31281061 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (fluticasone furoate-umeclidinium-vilanterol)
Number of subjects: 10355
Study 31281061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (fluticasone furoate-vilanterol)
Number of subjects: 10355
Study 28757912 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective lung ventilation (6 mL/kg tidal volume and 10 cm H2O PEEP)
Number of subjects: 60
Study 28757912 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (12 mL/kg tidal volume and 0 cm H2O PEEP)
Number of subjects: 60
Study 27180618 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 0
Study 27180618 — intervention group
Group type: EXPERIMENTAL
Intervention: Group conversation
Number of subjects: 0
Study 24162448 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lifestyle intervention group (moderate calorie and protein restriction, physical activity)
Number of subjects: 0
Study 24162448 — intervention group
Group type: COMPARATOR
Intervention: Baseline recommendations only (control group)
Number of subjects: 0
Study 22986783 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing promotion
Number of subjects: 461
Study 22986783 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 461
Study 20027349 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaferon (pediatric formulation)
Number of subjects: 0
Study 18575354 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Therapy (CBT)
Number of subjects: 40
Study 18575354 — intervention group
Group type: COMPARATOR
Intervention: Mutual Support Group Therapy (MST)
Number of subjects: 40
Study 14763633 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11728619 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9207389 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg oxamniquine
Number of subjects: 138
Study 9207389 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/kg praziquantel
Number of subjects: 138
Study 10146873 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol
Number of subjects: 145
Study 10146873 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol
Number of subjects: 145
Study 3301989 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary geriatric consultation team
Number of subjects: 404
Study 3301989 — intervention group
Group type: COMPARATOR
Intervention: Conventional patterns of care (control)
Number of subjects: 404